Abstract
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion 5-fluorouracil mg/m days 1-5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles.Fifteen patients were enrolled. The overall response rate was 60%. The median progression-free survival was 9.2 months (95% confidence interval [CI], 4.4-10.1 months) and the median overall survival was 19.4 months (95% CI, 8.9-21.1 months). Grade 3 neutropenia was observed in 3 patients (20%).The DOF plus trastuzumab seems active in HER-2 positive advanced gastric or GEJ cancer, final results of the phase II study are awaited.
Original language | English |
---|---|
Pages (from-to) | e10745 |
Journal | Medicine |
Volume | 97 |
Issue number | 20 |
DOIs | |
Publication status | Published - May 2018 |
Keywords
- Adenocarcinoma/drug therapy
- Administration, Intravenous
- Adult
- Antineoplastic Agents/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols
- Disease-Free Survival
- Docetaxel
- Esophagogastric Junction/pathology
- Female
- Fluorouracil/administration & dosage
- Humans
- Kaplan-Meier Estimate
- Male
- Neoplasm Staging
- Organoplatinum Compounds/administration & dosage
- Oxaliplatin
- Receptor, ErbB-2/antagonists & inhibitors
- Stomach/pathology
- Stomach Neoplasms/drug therapy
- Taxoids/administration & dosage
- Trastuzumab/administration & dosage